Miles, David

Trastuzumab emtansine for HER2-positive advanced breast cancer

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 3,834

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 922

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

Welslau, M., Diéras, V., Sohn, J., Hurvitz, S. A., Lalla, D., Fang, L., Althaus, B., Guardino, E., & Miles, D. (2014) · Cancer

HER2/EGFR in Cancer ResearchCancer survivorship and care

Cited by 126

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

Ilhan-Mutlu, A., Osswald, M., Liao, Y., Gömmel, M., Reck, M., Miles, D., Mariani, P., Gianni, L., Lutiger, B., Nendel, V., et al. (2016) · Molecular Cancer Therapeutics

Brain Metastases and TreatmentAngiogenesis and VEGF in Cancer

Cited by 119

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Brufsky, A., Kim, S. B., Zvirbule, Ž., Eniu, A., Mebis, J., Sohn, J. H., Wongchenko, M., Chohan, S., Amin, R., Yan, Y., et al. (2021) · Annals of Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 92

Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2

MILES, D., THOMSEN, L., BALKWILL, F., THAVASU, P., & MONCADA, S. (1994) · European Journal of Clinical Investigation

Nitric Oxide and Endothelin EffectsImmunotoxicology and immune responses

Cited by 26